glp-1 agonists cardiovascular diseases The Biology of Glucagon-like Peptide-1 Frontiers | Glucagon-like peptide-1 receptor

PMID: 40448382

A significant milestone was reached in 2014 when liraglutide, under the brand name Saxenda, was approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity [30]

are uncompensated consultants for Pfizer

In the brain, CSF secretion by the choroid plexus epithelial cells is also driven by the net movement of Na + from the blood into the cerebral ventricles

DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) revealed that the use of dapagliflozin in patients with New York Heart Association (NYHA) class II, III, or IV heart failure and an ejection fraction of 40% resulted in a lower risk of worsening heart failure and cardiovascular death

doi: 10.3390/ijms22157917